VGI Health Technology (XNEC:VTL) EV-to-FCF : (As of May. 30, 2024)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, VGI Health Technology's Enterprise Value is A$0.00 Mil. VGI Health Technology does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate VGI Health Technology's EV-to-FCF at this moment.

The historical rank and industry rank for VGI Health Technology's EV-to-FCF or its related term are showing as below:

XNEC:VTL's EV-to-FCF is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.455
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-30), VGI Health Technology's stock price is A$0.02. VGI Health Technology does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate VGI Health Technology's PE Ratio at this moment.

VGI Health Technology EV-to-FCF Historical Data

The historical data trend for VGI Health Technology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology EV-to-FCF Chart

VGI Health Technology Annual Data

Trend

EV-to-FCF

VGI Health Technology Semi-Annual Data

EV-to-FCF

Competitive Comparison of VGI Health Technology's EV-to-FCF

For the Biotechnology subindustry, VGI Health Technology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's EV-to-FCF falls into.

VGI Health Technology EV-to-FCF Calculation

VGI Health Technology's EV-to-FCF for today is calculated as:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	0.000	/
	=

VGI Health Technology (XNEC:VTL) EV-to-FCF Explanation

VGI Health Technology's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.02	/
	=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

VGI Health Technology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » EV-to-FCF

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines